HSP90 is a promising target in gemcitabine and 5-fluorouracil resistant pancreatic cancer

Apoptosis

Volumn 22, Issue 3, 2017, Pages 369-380

  Ghadban, Tarik ^a   Dibbern, Judith L ^a   Reeh, Matthias ^a   Miro, Jameel T ^a   Tsui, Tung Y ^b   Wellner, Ulrich ^c   Izbicki, Jakob R ^a   Güngör, Cenap ^a   Vashist, Yogesh K ^a,d  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b UNIVERSITY MEDICAL CENTER ROSTOCK   (Germany)

^c UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^d CANTONAL HOSPITAL AARAU   (Switzerland)

Author keywords

Anti tumor therapy; Geldanamycin; HSP90; Pancreatic cancer; Target therapy

Indexed keywords

17AAG; 17AEPGA; ALVESPIMYCIN; ANTINEOPLASTIC AGENT; CASPASE 3; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROURACIL; GEMCITABINE; HEAT SHOCK PROTEIN 27; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90; HEAT SHOCK PROTEIN 90 INHIBITOR; LIPOCORTIN 5; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; SOMATOMEDIN C RECEPTOR; UNCLASSIFIED DRUG; 17-(2-(PYRROLIDIN-1-YL)ETHYL)-AMINO-17-DEMETHOXYGELDANAMYCIN; 17-(DIMETHYLAMINOETHYLAMINO)-17-DEMETHOXYGELDANAMYCIN; BENZOQUINONE DERIVATIVE; DEOXYCYTIDINE; MACROCYCLIC LACTAM; TANESPIMYCIN; TUMOR PROTEIN;

ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER RESISTANCE; CELL ISOLATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; DRUG INHIBITION; DRUG TARGETING; HUMAN; HUMAN CELL; IC50; IN VITRO STUDY; INTRACELLULAR SIGNALING; MTT ASSAY; PANCREAS CANCER; PANCREATIC CANCER CELL LINE; PRIORITY JOURNAL; PROTEIN TARGETING; UPREGULATION; WESTERN BLOTTING; ADENOCARCINOMA; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; MOLECULARLY TARGETED THERAPY; PANCREAS TUMOR; PATHOLOGY; RECURRENT DISEASE; TUMOR CELL LINE;

ADENOCARCINOMA; APOPTOSIS; BENZOQUINONES; CELL LINE, TUMOR; DEOXYCYTIDINE; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; FLUOROURACIL; HSP90 HEAT-SHOCK PROTEINS; HUMANS; INHIBITORY CONCENTRATION 50; LACTAMS, MACROCYCLIC; MOLECULAR TARGETED THERAPY; NEOPLASM PROTEINS; PANCREATIC NEOPLASMS; RECURRENCE;

EID: 84996565982     PISSN: 13608185     EISSN: 1573675X     Source Type: Journal    
DOI: 10.1007/s10495-016-1332-4     Document Type: Article

References (48)

1. Herreros-Villanueva M, Hijona E, Cosme A, Bujanda L (2012) Adjuvant and neoadjuvant treatment in pancreatic cancer. World J Gastroenterol 18(14):1565–1572
2. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ (2007) Cancer statistics, 2007. CA Cancer J Clin 57(1):43–66
3. Verbeke CS, Leitch D, Menon KV, McMahon MJ, Guillou PJ, Anthoney A (2006) Redefining the R1 resection in pancreatic cancer. Br J Surg 93(10):1232–1237
4. Verbeke CS (2008) Resection margins and R1 rates in pancreatic cancer–are we there yet? Histopathology 52(7):787–796
5. Adler G, Seufferlein T, Bischoff SC, Brambs HJ, Feuerbach S, Grabenbauer G et al (2007) S3-guidelines “Exocrine pancreatic cancer” 2007. Z Gastroenterol 45(6):487–523
6. Bergman AM, Pinedo HM, Peters GJ (2002) Determinants of resistance to 2′,2′-difluorodeoxycytidine (gemcitabine). Drug Resist Updates 5(1):19–33
7. Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y et al (2011) FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364(19):1817–1825
8. Conroy T, Gavoille C, Adenis A (2011) Metastatic pancreatic cancer: old drugs, new paradigms. Curr Opin Oncol 23(4):390–395
9. Li J, Saif MW (2009) Any progress in the management of advanced pancreatic cancer? JOP 10(4):361–365
10. Makrilia N, Syrigos KN, Saif MW (2011) Updates on treatment of gemcitabine-refractory pancreatic adenocarcinoma. JOP 12(4):351–354
11. Almoguera C, Shibata D, Forrester K, Martin J, Arnheim N, Perucho M (1988) Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 53(4):549–554
12. Ahsan A, Ramanand SG, Whitehead C, Hiniker SM, Rehemtulla A, Pratt WB et al (2012) Wild-type EGFR is stabilized by direct interaction with HSP90 in cancer cells and tumors. Neoplasia 14(8):670–677
13. Lang SA, Moser C, Gaumann A, Klein D, Glockzin G, Popp FC et al (2007) Targeting heat shock protein 90 in pancreatic cancer impairs insulin-like growth factor-I receptor signaling, disrupts an interleukin-6/signal-transducer and activator of transcription 3/hypoxia-inducible factor-1alpha autocrine loop, and reduces orthotopic tumor growth. Clin Cancer Res 13(21):6459–6468
14. Talar-Wojnarowska R, Malecka-Panas E (2006) Molecular pathogenesis of pancreatic adenocarcinoma: potential clinical implications. Med Sci Monit 12(9):RA186–RA93
15. Samuel N, Hudson TJ (2012) The molecular and cellular heterogeneity of pancreatic ductal adenocarcinoma. Nat Rev Gastroenterol Hepatol 9(2):77–87
16. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S et al (2007) Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25(15):1960–1966
17. Burrows F, Zhang H, Kamal A (2004) Hsp90 activation and cell cycle regulation. Cell Cycle 3(12):1530–1536
18. Schmitt E, Gehrmann M, Brunet M, Multhoff G, Garrido C (2007) Intracellular and extracellular functions of heat shock proteins: repercussions in cancer therapy. J Leukoc Biol 81(1):15–27
19. Wandinger SK, Richter K, Buchner J (2008) The Hsp90 chaperone machinery. J Biol Chem 283(27):18473–18477
20. Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100(1):57–70
21. Neckers L (2007) Heat shock protein 90: the cancer chaperone. J Biosci 32(3):517–530
22. Kamal A, Thao L, Sensintaffar J, Zhang L, Boehm MF, Fritz LC et al (2003) A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature 425(6956):407–410
23. Calderwood SK, Khaleque MA, Sawyer DB, Ciocca DR (2006) Heat shock proteins in cancer: chaperones of tumorigenesis. Trends Biochem Sci 31(3):164–172
24. Xue M, Cao X, Zhong Y, Kuang D, Liu X, Zhao Z et al (2012) Insulin-like growth factor-1 receptor (IGF-1R) kinase inhibitors in cancer therapy: advances and perspectives. Curr Pharm Des 18(20):2901–2913
25. Ryu YL, Jung KH, Son MK, Yan HH, Kim SJ, Shin S et al (2014) Anticancer activity of HS-527, a novel inhibitor targeting PI3-kinase in human pancreatic cancer cells. Cancer Lett 353(1):68–77
26. Li J, Kleeff J, Giese N, Buchler MW, Korc M, Friess H (2004) Gefitinib (‘Iressa’, ZD1839), a selective epidermal growth factor receptor tyrosine kinase inhibitor, inhibits pancreatic cancer cell growth, invasion, and colony formation. Int J Oncol 25(1):203–210
27. Hollingshead M, Alley M, Burger AM, Borgel S, Pacula-Cox C, Fiebig HH et al (2005) In vivo antitumor efficacy of 17-DMAG (17-dimethylaminoethylamino-17-demethoxygeldanamycin hydrochloride), a water-soluble geldanamycin derivative. Cancer Chemother Pharmacol 56(2):115–125
28. Smith V, Sausville EA, Camalier RF, Fiebig HH, Burger AM (2005) Comparison of 17-dimethylaminoethylamino-17-demethoxy-geldanamycin (17DMAG) and 17-allylamino-17-demethoxygeldanamycin (17AAG) in vitro: effects on Hsp90 and client proteins in melanoma models. Cancer Chemother Pharmacol 56(2):126–137
29. Kalinina T, Gungor C, Thieltges S, Moller-Krull M, Penas EM, Wicklein D et al (2010) Establishment and characterization of a new human pancreatic adenocarcinoma cell line with high metastatic potential to the lung. BMC Cancer 10:295
30. Bruns CJ, Harbison MT, Kuniyasu H, Eue I, Fidler IJ (1999) In vivo selection and characterization of metastatic variants from human pancreatic adenocarcinoma by using orthotopic implantation in nude mice. Neoplasia 1(1):50–62
31. Neoptolemos JP, Stocken DD, Bassi C, Ghaneh P, Cunningham D, Goldstein D et al (2010) Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. Jama 304(10):1073–1081
32. Ohhashi S, Ohuchida K, Mizumoto K, Fujita H, Egami T, Yu J et al (2008) Down-regulation of deoxycytidine kinase enhances acquired resistance to gemcitabine in pancreatic cancer. Anticancer Res 28(4B):2205–2212
33. El Maalouf G, Le Tourneau C, Batty GN, Faivre S, Raymond E (2009) Markers involved in resistance to cytotoxics and targeted therapeutics in pancreatic cancer. Cancer Treat Rev 35(2):167–174
34. Adjei AA (2001) Blocking oncogenic Ras signaling for cancer therapy. J Natl Cancer Inst 93(14):1062–1074
35. Nair PN, De Armond DT, Adamo ML, Strodel WE, Freeman JW (2001) Aberrant expression and activation of insulin-like growth factor-1 receptor (IGF-1R) are mediated by an induction of IGF-1R promoter activity and stabilization of IGF-1R mRNA and contributes to growth factor independence and increased survival of the pancreatic cancer cell line MIA PaCa-2. Oncogene 20(57):8203–8214
36. van der Veeken J, Oliveira S, Schiffelers RM, Storm G, van Bergen En, Henegouwen PM, Roovers RC (2009) Crosstalk between epidermal growth factor receptor- and insulin-like growth factor-1 receptor signaling: implications for cancer therapy. Curr Cancer Drug Targets 9(6):748–760
37. Saridaki Z, Georgoulias V, Souglakos J (2010) Mechanisms of resistance to anti-EGFR monoclonal antibody treatment in metastatic colorectal cancer. World J Gastroenterol 16(10):1177–1187
38. Sawai A, Chandarlapaty S, Greulich H, Gonen M, Ye Q, Arteaga CL et al (2008) Inhibition of Hsp90 down-regulates mutant epidermal growth factor receptor (EGFR) expression and sensitizes EGFR mutant tumors to paclitaxel. Cancer Res 68(2):589–596
39. Ogata M, Naito Z, Tanaka S, Moriyama Y, Asano G (2000) Overexpression and localization of heat shock proteins mRNA in pancreatic carcinoma. J Nippon Med Sch 67(3):177–185
40. Cao X, Bloomston M, Zhang T, Frankel WL, Jia G, Wang B et al (2008) Synergistic antipancreatic tumor effect by simultaneously targeting hypoxic cancer cells with HSP90 inhibitor and glycolysis inhibitor. Clin Cancer Res 14(6):1831–1839
41. Song D, Chaerkady R, Tan AC, Garcia-Garcia E, Nalli A, Suarez-Gauthier A et al (2008) Antitumor activity and molecular effects of the novel heat shock protein 90 inhibitor, IPI-504, in pancreatic cancer. Mol Cancer Ther 7(10):3275–3284
42. Garrido C, Arrigo A, Solary E (2000) Hsp27: a small heat shock protein with protective and tumorigenic effects. Recent Res Dev 2:105–114
43. Lanneau D, de Thonel A, Maurel S, Didelot C, Garrido C (2007) Apoptosis versus cell differentiation: role of heat shock proteins HSP90, HSP70 and HSP27. Prion 1(1):53–60
44. Lee CH, Hong HM, Chang YY, Chang WW (2012) Inhibition of heat shock protein (Hsp) 27 potentiates the suppressive effect of Hsp90 inhibitors in targeting breast cancer stem-like cells. Biochimie 94(6):1382–1389
45. Garrido C, Gurbuxani S, Ravagnan L, Kroemer G (2001) Heat shock proteins: endogenous modulators of apoptotic cell death. Biochem Biophys Res Commun 286(3):433–442
46. Lavoie JN, Lambert H, Hickey E, Weber LA, Landry J (1995) Modulation of cellular thermoresistance and actin filament stability accompanies phosphorylation-induced changes in the oligomeric structure of heat shock protein 27. Mol Cell Biol 15(1):505–516
47. Samali A, Orrenius S (1998) Heat shock proteins: regulators of stress response and apoptosis. Cell Stress Chaperones 3(4):228–236
48. Sato S, Fujita N, Tsuruo T (2000) Modulation of Akt kinase activity by binding to Hsp90. Proc Natl Acad Sci USA 97(20):10832–10837